Why Numinus is developing psilocybin tea for research

Numinus Wellness (TSE:NUMI) has developed a psilocybin-containing tea bag for clinical research and potentially for clients in psychedelic-assisted therapy.

The Vancouver–based company’s strategy differs from that of other companies that have popped up in recent years with the intent of creating bespoke psychedelic compounds with patent protection. Some companies, for instance, have created deuterated psilocybin analogs with a shortened half-life. Others have synthesized patentable compounds inspired by other classic psychedelics such as DMT or LSD.

Conversely, Numinus and its rival Compass Pathways (Nasdaq:CMPS) intend to provide psilocybin-assisted therapy. While Numinus is using validated strains of Psilocybe cubensis in a tea, Compass Pathways is exploring a synthetic, high-purity polymorphic formulation of psilocybin.

Numinus was the first publicly-traded company to win a license from Health Canada related to psilocybin.

Numinus plans o…

Read more
  • 0